Mark Agulnik
马克·阿古尔尼克
MD
Professor of Medicine, Division of Hematology/Oncology血液学/肿瘤学教授
👥Biography 个人简介
Recognized authority in gastrointestinal stromal tumors (GIST) and soft tissue sarcomas. Specializes in mechanisms of imatinib resistance in GIST and the rational use of sequential kinase inhibitors (imatinib, sunitinib, regorafenib, ripretinib) in advanced GIST.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GIST Imatinib Resistance
Characterized secondary KIT and PDGFRA mutations driving imatinib resistance in GIST and conducted translational studies guiding the clinical development of later-line agents including regorafenib and ripretinib.
Representative Works 代表性著作
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Cancer Cell (2019)
Mechanistic and preclinical study establishing the basis for ripretinib's broad activity against imatinib-resistant KIT mutations in GIST.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 马克·阿古尔尼克 的研究动态
Follow Mark Agulnik's research updates
留下邮箱，当我们发布与 Mark Agulnik（Northwestern University / City of Hope）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment